Marlborough

MARLBOROUGH, Massachusetts, May 9, 2011 - -- Data Presented at Heart Rhythm 2011 Show Durable Pulmonary Vein Isolation of 86% -- CardioFocus, Inc., developer of the HeartLight Endoscopic Ablation System for the transcatheter treatment of Atrial Fibrillation (AF), announced its technology enables a Pulmonary Vein (PV) acute isolation rate of nearly 99%, with approximately 86% of PVs remaining persistently isolated after three months.

MARLBOROUGH, Massachusetts, January 25, 2011 - CardioFocus announced that two "live cases" using its Endoscopic Ablation System were recently conducted.

MARLBOROUGH, Massachusetts and PUNE, India, January 5, 2011 - --Companies to Jointly Develop Process Design Packages (PDPs) that Enable Lowest Cost, Commercial-Scale Ethanol Production from Sugarcane, Corn and Wheat Residuals-- --Qteros' Consolidated Bioprocessing (CBP) Platform to Serve as PDP Technology Foundation; Enables Highly Streamlined Engineering Design and Delivers World-Class Economic Returns to Ethanol Producers-- --Praj's Experience and Installed Base of More than 450 Ethanol Plants Around the World Accelerates Commercialization Pathway for PDPs-- Qteros, Inc., the developer of a unique and highly efficient Consolidated Bioprocessing (CBP) platform for the lowest cost production of cellulosic ethanol, and Praj Industries Limited (BSE: 522205 | NSE: PRAJIND), a global leader in the development of innovative technology and engineering solutions for the production of biofuels and biochemicals, today announced a strategic partnership to accelerate commercialization efforts for industrial-scale cellulosic ethanol production.